Added to YB: 2026-09-02
Pitch date: 2026-08-28
TNGX [bullish]
Tango Therapeutics, Inc.
-3.99%
current return
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
Market Cap
$3.9B
Pitch Price
$23.28
Price Target
47.92
Dividend
N/A
EV/EBITDA
-23.82
P/E
-25.51
EV/Sales
54.88
Sector
Biotechnology
Category
growth
Does it take 2 to tango, or just 1? : An Analysis of Tango Therapeutics ($TNGX)
TNGX: Tango’s lead cancer drug, vopimetostat, may be mispriced because early human data showed efficacy without the severe bone-marrow toxicity that hurt older drugs: no severe blood-cell drops at target doses, 7.2 months of disease control, and tumor shrinkage in 25% of advanced pancreatic cancer patients. A $47.92 target implies 89% upside, while roughly $1B of cash funds operations into 2029; key risks are weaker durability in larger trials or unexpected toxicity from combination dosing.
Read full article (5 min)